A Study of Efgartigimod in Patients With IgG4-Related Disease
Running, not enrolling · Phase 2
Conditions studied: IgG4-related Disease
In brief
The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * pancreas Participants will: * Receive efgartigimod once weekly for up to 12 weeks * Visit the clinic every one to six weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on efgartigimod
Key facts
- Study ID
- NCT07025330
- Run by
- Stanford University
- People needed
- 5
- Starts
- 2025-11-12
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.